Paragon Care (FRA:PXS) Research & Development: €0 Mil (TTM As of Dec. 2025)


FRA:PXS Paragon Care Ltd FRA:PXS
56 GF Score
Price €0.07
GF Value €0.20
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Paragon Care Research & Development?

Paragon Care FRA:PXS -6.99% 56 Research & Development is €0 Mil as of Dec. 2025. GuruFocus rates FRA:PXS with a GF Score™ of 56/100 and a GF Value™ of €0.20 (Possible Value Trap). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Paragon Care's Research & Development for the six months ended in Dec. 2025 was €0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0 Mil.

Paragon Care  (FRA:PXS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Paragon Care Research & Development Related Terms

Paragon Care Research & Development Historical Data

* Premium members only.

The historical data trend for Paragon Care's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paragon Care Research & Development Chart

Paragon Care Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Paragon Care Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:PXS
56GF Score
Paragon Care Ltd FRA:PXS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paragon Care Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0 Mil mean?
Paragon Care (FRA:PXS) has a Research & Development of €0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Paragon Care and its competitors.
Is Paragon Care's Research & Development too high?
Paragon Care's current Research & Development is €0 Mil. Overall, Paragon Care has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Paragon Care's Research & Development compare to MCK and CAH?
Paragon Care's Research & Development of €0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Paragon Care and its competitors. Paragon Care's current Research & Development is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paragon Care stock overvalued right now?
Based on GuruFocus' analysis, Paragon Care (FRA:PXS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.20, compared to a current price of €0.07 — trading 66.8% below its estimated fair value. The current Research & Development is €0 Mil. Paragon Care's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Paragon Care (FRA:PXS), the current Research & Development is €0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Paragon Care (FRA:PXS) Overvalued in 2026?

Based on GuruFocus' analysis, Paragon Care stock appears to be undervalued. The current stock price of €0.07 is trading 66.8% below its estimated GF Value™ of €0.20. GuruFocus considers Paragon Care to be Possible Value Trap.

Key valuation signals for FRA:PXS:

  • Research & Development: €0 Mil
  • GF Value™: €0.20 vs. price of €0.07 (66.8% below fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the FRA:PXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Paragon Care Business Description

Other Exchanges PGC:Australia
Address 77-97 Ricketts Road, Mount Waverley, Melbourne, VIC, AUS, 3149
Paragon Care Ltd is a medical device company. The company provides medical equipment, devices, and consumables medical products to the healthcare market. The company provides solutions to various healthcare markets, aged care, and veterinary markets. The group is organized into two operating segments: ParagonCare and CH2 Holdings and the majority of its revenues are generated from the CH2 Holdings segment engaged in the distribution of pharmaceuticals, medical consumables, nutritional, and over-the-counter products to the healthcare market.
56GF Score

Get the complete analysis for FRA:PXS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.20
GF Value